A 29-year-old woman is evaluated in the clinic for a follow-up visit. Six weeks ago, she w… — USMLE Step 3

A $29$ -year-old woman is evaluated in the clinic for a follow-up visit. Six weeks ago, she was diagnosed with Graves disease after presenting with a $3$ -month history of weight loss, heat intolerance, and palpitations. At that time, laboratory studies showed a markedly suppressed thyroid-stimulating hormone (TSH) level and elevated free thyroxine (T4) and total triiodothyronine (T3) levels. She was started on methimazole $20$ mg daily.

Today, she reports feeling much better. She has regained $2$ kg ( $4.4$ lbs) and her palpitations and heat intolerance have resolved. Her heart rate is $72$ /min and blood pressure is $112/70$ mm Hg. Physical examination shows a small, non-tender, symmetric goiter. There is no tremor or exophthalmos.

Repeat laboratory studies show:
Thyroid-stimulating hormone (TSH): $<0.01$ $\mu$ U/mL (reference: $0.4-4.2$ $\mu$ U/mL)
Free thyroxine (T4): $1.2$ ng/dL (reference: $0.8-1.8$ ng/dL)
Total triiodothyronine (T3): $130$ ng/dL (reference: $80-200$ ng/dL)

Which of the following is the best next step in the management of this patient?

A
Increase the dose of methimazole
B
Continue methimazole at the current dose
Decrease the dose of methimazoleAnswer
D
Order a radioactive iodine uptake scan
E
Discontinue methimazole and schedule radioactive iodine ablation

Answer

Decrease the dose of methimazole

The correct next step is to decrease the dose of methimazole. In the treatment of Graves disease, an initial induction dose of a thionamide (such as methimazole) is used to rapidly inhibit thyroid hormone synthesis. Once the patient achieves clinical euthyroidism (resolution of symptoms) and biochemical euthyroidism (normalization of Free T4 and Total T3), the methimazole dose must be reduced (typically by

30\%

50\%

) to a maintenance dose. Continuing the high induction dose will inevitably result in iatrogenic hypothyroidism. The persistently suppressed TSH is a normal, expected finding at this stage; TSH recovery lags behind the normalization of peripheral thyroid hormones by several months due to prolonged suppression of the hypothalamic-pituitary-thyroid axis. Therefore, during the first few months of therapy, dose adjustments must be guided solely by Free T4 and Total T3 levels, not TSH.

Step-by-Step Solution

Evaluate the patient's clinical status and laboratory results.

The patient is clinically euthyroid (asymptomatic, weight gained) and biochemically euthyroid (Free T4 and T3 have normalized). However, TSH remains suppressed.

Determining the current thyroid status is essential for adjusting antithyroid medication.

Interpret the suppressed TSH in the context of recent Graves disease treatment.

The suppressed TSH is an expected physiologic finding. TSH recovery lags behind peripheral hormone normalization by several months due to prolonged prior suppression of the pituitary gland.

TSH should not be used to titrate methimazole in the first few months; Free T4 and T3 are the reliable markers.

Determine the appropriate dose adjustment for methimazole.

Because the patient has achieved euthyroidism on the initial high induction dose, the dose must now be decreased (typically by 30% to 50%) to a lower maintenance dose.

Continuing the high induction dose will lead to iatrogenic hypothyroidism, as the thyroid is now adequately blocked.

Key Concept

During the first several months of thionamide therapy for Graves disease, dosing must be titrated based on Free T4 and Total T3 rather than TSH, which remains suppressed. Once euthyroidism is achieved, the induction dose must be decreased to a maintenance dose to prevent hypothyroidism.

Estimated Time:1m 15s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic